Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03553004 | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial(NIRA-PANC) | unknown | Phase 2 | 18 | University of Kansas Medical CenterOTHER |
| 1 |
| May 19, 2023 |
| clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Devalingam MahalingamOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02578732 | FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 28 | Brown UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer(10) | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05616494 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer | unknown | Phase 2 | 53 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02707159 | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients(PACT-ACT-v6) | completed | Phase 2 | 70 | Helse Stavanger HFOTHER_GOV | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 37 | Kyntra BioINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02028806 | mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer(ALPINE) | completed | Phase 1 / Phase 2 | 217 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03977272 | Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | completed | Phase 2 | 110 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT05679583 | Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05679050 | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 62 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03099265 | Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Yale UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01845805 | Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | completed | Phase 2 | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05566743 | A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas | unknown | Phase 2 | 40 | Menoufia UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03158779 | Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 45 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03487016 | First-line Therapy in Metastatic PDAC(FOOTPATH) | unknown | Phase 2 | 270 | Ludwig-Maximilians - University of MunichOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04769414 | Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) | completed | Phase 2 | 48 | Menoufia UniversityOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02080221 | BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 50 | Brown UniversityOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03086369 | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 184 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT04418739 | Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes | unknown | Phase 2 | 122 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05212025 | Adavosertib and Gemcitabine in Advanced Pancreatic | withdrawn | Phase 2 | 0 | James Cleary, MD, PhDOTHER | 0 | Jun 14, 2022 | clinicaltrials |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients(PGPC1) | terminated | Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT02022033 | BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 25 | Brown UniversityOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05399394 | Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer(FOLRT) | unknown | Phase 2 | 50 | Campus Bio-Medico UniversityOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
Data updated 24 days agoSource updated May 23, 2023source: clinicaltrials